SUPPLEMENTARY ONLINE CONTENT

Supplementary Figure S1. Directed acyclic graph with level of income as exposure and major adverse clinical events as outcome

Supplementary Figure S2. Number of events, event rates, and hazard ratios (95% confidence intervals) between income and secondary clinical endpoints among **men** in study population I and II.

Supplementary Figure S3. Number of events, event rates, and hazard ratios (95% confidence intervals) between income and secondary clinical endpoints among **women** in study population I and II.

Supplementary Figure S4. Cumulative incidence on the association between **income** and secondary clinical outcomes adjusted for age and ethnicity.

Supplementary Figure S5. Cumulative incidence on the association between **education** and secondary clinical outcomes adjusted for age and ethnicity.

Supplementary Figure S6. Number of events, event rates, and hazard ratios (95% confidence intervals) on the association between income and non-persistence to **statins** as well as the mediating effect on the association between income and risk of MACE among **men**, adjusted for age and ethnicity.

Supplementary Figure S7. Number of events, event rates, and hazard ratios (95% confidence intervals) on the association between income and non-persistence to **antiplatelets** as well as the mediating effect on the association between income and risk of MACE among **men**, adjusted for age and ethnicity.


Supplementary Table S1. ATC-, ICD-10-, and procedure codes

Supplementary Table S2. Baseline characteristics of study population II (education as exposure) stratified by sex.

Supplementary Table S3. Events, event rates (95% CI), and hazard ratios (95% CI) for the association between **income** and risk of non-persistence to medication and clinical events using none or 30-days window of initiation of medication

Supplementary Table S4. Events, event rates (95% CI), and hazard ratios (95% CI) for the association between **education** and risk of non-persistence to medication and clinical events using none or 30-days window of initiation of medication

Supplementary Figure S1. Directed acyclic graph with major adverse cardiovascular events (MACE) as outcome



Minimal adjustment after adjusting for initiation: education, civil status, ethnicity, age, comorbidities somatic, comorbidities psychiatric, sex

Supplementary Figure S2. Number of events, event rates, and hazard ratios (95% confidence intervals) between income and secondary clinical endpoints among **men** in study population I and II.


							All-cause	death						
		Ur	nadju	sted			I	Model I			I	Model II		
	No. of	Event rate pr.			HR	No. of	Event rate pr.		HR	No. of	Event rate pr.		HR	
	events	100,000 pr. yrs.				events	100,000 pr. yrs.			events	100,000 pr. yrs.			
Study po	pulation I (income as exposure))						1			1		
Low	2,318	16.7 (16.0-17.4)			1 (reference)	2,018	13.3 (12.7-13.9)	1	1 (reference)	1,702	11.2 (10.6-11.8)		1 (reference)	
Middle	1,428	8.4 (8.0-8.8)			0.50 (0.47-0.53)	1,459	8.3 (7.9-8.8)	HE H	0.65 (0.60-0.70)	1,461	8.3 (7.9-8.8)	H	0.77 (0.71-0.83)	
High	816	4.4 (4.1-4.7)			0.26 (0.24-0.28)	1,169	6.3 (5.9-6.8)	-	0.48 (0.44-0.53)	1,782	9.4 (6.9-13.4)	H = H	0.66 (0.58-0.74)	
		(education as exposi	ure)											
Low	2,015	12.5 (11.9-13.0)			1 (reference)	1,803	11.0 (10.5-11.5)	1	1 (reference)	1,583	9.7 (9.3-10.2)	•	1 (reference)	
Middle	1,909	8.0 (7.7-8.4)			0.65 (0.61-0.69)	2,061	8.7 (8.3-9.1)	H==1	0.81 (0.76-0.86)	2,095	8.9 (8.5-9.3)	н=н	0.90 (0.85-0.96)	
High	638	6.7 (6.2-7.2)			0.54 (0.49-0.59)	667	7.0 (6.5-7.5)	H	0.66 (0.60-0.72)	740	7.2 (6.5-7.9)	H=	0.78 (0.70-0.88)	
			0.2	0.6				0.4 0.7	1			0.5 0.75 1		
							Cardiac	leath						
		Ur	nadju	sted			I	Model I			Model II of Event rate pr. HR			
	No. of	Event rate pr.			HR	No. of	Event rate pr.		HR	No. of	Event rate pr.		HR	
	events	100,000 pr. yrs.				events	100,000 pr. yrs.			events	100,000 pr. yrs.			
Study po	pulation I (income as exposure)		1			- 1				1		
Low	506	3.6 (3.3-4.0)			1 (reference)	441	2.9 (2.6-3.2)	•	1 (reference)	368	2.4 (2.2-2.7)	•	1 (reference)	
Middle	349	2.1 (1.8-2.3)		HEH.	0.56 (0.49-0.63)	356	2.0 (1.8-2.3)	HEH	0.72 (0.62-0.82)	358	2.0 (1.8-2.3)	⊢	0.87 (0.74-1.01)	
High	182	1.0 (0.8-1.1)			0.26 (0.22-0.31)	257	1.4 (1.2-1.7)	H H	0.47 (0.39-0.57)	351	1.9 (1.5-2.4)	⊢	0.62 (0.48-0.80)	
Study po	pulation II	(education as exposi	ure)											
Low	481	3.0 (2.7-3.3)			1 (reference)	432	2.6 (2.4-2.9)	•	1 (reference)	375	2.3 (2.1-2.5)	•	1 (reference)	
Middle	408	1.7 (1.6-1.9)		H	0.58 (0.51-0.66)	438	1.9 (1.7-2.0)	H=H	0.72 (0.63-0.82)	445	1.9 (1.7-2.1)	H=	0.81 (0.71-0.93)	
High	148	1.6 (1.3-1.8)		H	0.53 (0.44-0.63)	152	1.6 (1.4-1.9)	H=H	0.62 (0.52-0.75)	166	1.6 (1.3-2.0)		0.75 (0.59-0.95)	
			0.2	0.6	_ 1			0.2 0.6 1				0.4 0.7 1		
					-		Cardiac rea	lmission						
		Ur	nadju	sted			I	Model I			I	Model II		
	No. of	Event rate pr.			HR	No. of	Event rate pr.		HR	No. of	Event rate pr.		HR	
	events	100,000 pr. yrs.				events	100,000 pr. yrs.			events	100,000 pr. yrs.			
Study po	pulation I (income as exposure)	1				1				1		
Low	3,380	34.5 (33.3-35.7)		•	1 (reference)	3,376	30.9 (29.5-32.3)	•	1 (reference)	3,078	27.5 (26.0-29.1)		1 (reference)	
Middle	3,219	25.1 (24.2-26.0)		•	0.78 (0.75-0.81)	3,289	24.9 (23.9-25.9)	•	0.83 (0.79-0.86)	3,275	24.6 (23.7-25.7)	H	0.89 (0.84-0.93)	
High	2,946	20.2 (19.5-20.9)			0.63 (0.61-0.66)	3,296	23.0 (22.0-24.1)	-	0.73 (0.70-0.77)	3,616	24.9 (23.3-26.7)	+■+	0.80 (0.75-0.86)	
Study po	pulation II	(education as exposi	ure)											
Low	3,512	29.6 (28.6-30.6)		•	1 (reference)	3,417	28.0 (26.9-29.2)	•	1 (reference)	3,259	26.8 (25.7-28.0)	•	1 (reference)	
Middle	4,403	24.5 (23.8-25.2)		•	0.87 (0.84-0.90)	4,504	25.3 (24.5-26.2)	•	0.92 (0.89-0.96)	4,528	25.5 (24.7-26.4)	H	0.97 (0.93-1.00)	
High	1,630	22.1 (21.0-23.2)		•	0.79 (0.76-0.83)	1,642	22.2 (21.1-23.6)	-	0.83 (0.79-0.87)	1,822	23.3 (21.6-25.0)	H=-4	0.93 (0.88-0.99)	
		0).5	0.75 1				0.6 0.8 1	-			0.7 0.85 1		
								-10 010 1				J. 7 V.O.J 1		

Supplementary Figure S3. Number of events, event rates, and hazard ratios (95% confidence intervals) between income and secondary clinical endpoints among **women** in study population I and II.

						All-cause	death						
		U	nadjusted				Model I]	Model II		
	No. of events	Event rate pr. 100,000 pr. yrs.		HR	No. of events	Event rate pr. 100,000 pr. yrs.		HR	No. of events	Event rate pr. 100,000 pr. yrs.		HR	
Low Middle High	2,039 784 270	ncome as exposure 21.1 (20.2-22.0) 10.5 (9.8-11.2) 4.9 (4.3-5.5) education as expos		1 (reference) 0.50 (0.46-0.54) 0.23 (0.20-0.26)	1,860 913 486	17.4 (16.6-18.3) 12.2 (11.4-13.0) 8.8 (7.7-10.2)	ни	1 (reference) 0.72 (0.66-0.78) 0.49 (0.42-0.56)	1,692 937 771	15.6 (14.7-16.5) 12.6 (11.8-13.6) 12.8 (9.8-17.2)	I	1 (reference) 0.82 (0.74-0.90) 0.64 (0.52-0.79)	
Low Middle High	2,077 758 258	18.9 (18.1-19.7) 9.5 (8.9-10.2) 6.9 (6.1-7.8)	-	1 (reference) 0.51 (0.47-0.55) 0.37 (0.32-0.42)	1,826 883 337	16.1 (15.4-16.8) 11.3 (10.5-12.1) 9.3 (8.2-10.5)	HIH	1 (reference) 0.70 (0.64-0.76) 0.56 (0.50-0.64)	1,686 928 382	15.0 (14.3-15.7) 11.8 (11.0-12.7) 10.2 (8.7-12.0)	H#H H#H	1 (reference) 0.76 (0.70-0.83) 0.71 (0.61-0.84)	
			0.2 0.6 1	1			0.4 0.7	1			0.4 0.7 1		
						Cardiac							
	Unadjusted						Model I			Model II No. of Event rate pr. HR			
	No. of events	Event rate pr. 100,000 pr. yrs.		HR	No. of events	Event rate pr. 100,000 pr. yrs.		HR	No. of events	Event rate pr. 100,000 pr. yrs.		HR	
Low Middle High	411 147 54	ncome as exposure 4.3 (3.9-4.7) 2.0 (1.7-2.3) 1.0 (0.7-1.3) on II (education as 3.8 (3.4-4.2) 1.8 (1.5-2.1) 1.4 (1.0-1.8)		1 (reference) 0.46 (0.38-0.55) 0.23 (0.17-0.30) 1 (reference) 0.49 (0.40-0.59) 0.37 (0.28-0.49)	375 178 95 362 170 66		0.25 0.5 0.75	1 (reference) 0.68 (0.57-0.82) 0.47 (0.34-0.64) 1 (reference) 0.68 (0.56-0.82) 0.55 (0.41-0.75)	337 184 136 334 179 74	3.1 (2.8-3.5) 2.5 (2.1-2.9) 2.3 (1.5-3.7) 3.0 (2.7-3.3) 2.3 (1.9-2.7) 2.0 (1.4-3.0)	0.25 0.5 0.75 1	1 (reference) 0.80 (0.65-0.98) 0.58 (0.35-0.96) 1 (reference) 0.76 (0.62-0.92) 0.72 (0.48-1.06)	
						Cardiac rea							
	No. of events	Event rate pr. 100,000 pr. yrs.	nadjusted	HR	No. of events	Event rate pr. 100,000 pr. yrs.	Model I	HIR	No. of events	Event rate pr. 100,000 pr. yrs.	Model II	HR	
Low Middle High Study pop Low Middle	2,404 1,433 790 pulation II (2,646 1,409	ncome as exposure 34.5 (33.1-35.9) 25.2 (23.9-26.5) 17.4 (16.2-18.6) (education as expos 32.9 (31.7-34.2) 22.8 (21.6-24.0)	sure)	1 (reference) 0.75 (0.71-0.80) 0.55 (0.52-0.60) 1 (reference) 0.76 (0.72-0.80)	2,390 1,500 1,000 2,525 1,488	30.5 (29.0-32.1) 26.4 (24.9-28.0) 23.0 (20.9-25.4) 30.1 (28.7-31.5) 24.8 (23.4-26.3)	HIH HIH	1 (reference) 0.85 (0.80-0.90) 0.75 (0.69-0.81) 1 (reference) 0.86 (0.81-0.91)	2,278 1,502 1,342 2,436 1,505	28.2 (26.3-30.3) 26.7 (25.1-28.4) 28.1 (22.3-34.6) 28.8 (27.4-30.3) 25.1 (23.6-26.7)	H.	1 (reference) 0.91 (0.85-0.97) 0.89 (0.79-1.00) 1 (reference) 0.90 (0.85-0.95)	
High	572	19.2 (17.7-20.8)	0.5 0.75	0.65 (0.60-0.71)	626	22.0 (20.1-24.2)	0.5 0.75	0.77 (0.71-0.83)	691	24.5 (21.8-27.7)	0.5 0.75 1	0.91 (0.82-1.00)	


Supplementary Figure S4. Cumulative incidence on the association between income and secondary outcomes adjusted for age and ethnicity.

Study population I (income as exposure)



Supplementary Figure S5. Cumulative incidence on the association between education and secondary outcomes adjusted for age and ethnicity.

Study population II (education as exposure)



Supplementary Figure S6. Number of events, event rates, and hazard ratios (95% confidence intervals) on the association between income and non-persistence to **statins** as well as the mediating effect on the association between income and risk of MACE among **men**, adjusted for age and ethnicity

				Non-persistence to	statins				
		ı	Jnadjusted			I	Model I		
	No. of events	Event rate per 100,000 pr. yrs.		HR	No. of events	Event rate per 100,000 pr. yrs.		HR	
Study pop	ulation I (ir	ncome as exposure)				· · ·		1	
Low	2,381	20.7 (19.9-21.6)		1 (reference)	2,651	21.5 (20.5-22.5)		1 (reference)	
Middle	2,321	16.1 (15.4-16.7)	HEH	0.77 (0.73-0.82)	2,397	16.1 (15.5-16.8)	HEH	0.75 (0.71-0.79)	
High	2,227	13.8 (13.2-14.4)	•	0.66 (0.62-0.69)	2,312	14.4 (13.7-15.1)	н	0.65 (0.61-0.70)	
Study pop	ulation II (education as exposu	ıre)						
Low	2,358	17.1 (16.4-17.8)		1 (reference)	2,365	16.9 (16.2-17.6)		1 (reference)	
Middle	3,261	16.1 (15.6-16.7)	,	0.94 (0.90-1.00)	3,260	16.2 (15.7-16.8)	н	0.96 (0.91-1.01)	
High	1,310	16.2 (15.4-17.1)	-	0.94 (0.88-1.01)	1,305	16.2 (15.3-17.1)	н	0.95 (0.89-1.02)	
								上	
			0.5 0.75	1			0.5 0.75	1	
			The mediat	ting effect of non-persiste	nce to statins	s among men			
Level of in	ncome	Total effect	(HR, 95% CI)	Direct effect (HR, 95%	CI) Indirec	et effect (HR, 95% CI) Mediated pr	oportion (%)	
Low		1 (reference)		1 (reference)	1 (refe	rence)	1 (reference))	
Middle		0.78 (0.75-0.81	1)	0.82 (0.79-0.85)	0.96 (0	0.95-0.96)	18.1 (15.4-2	18.1 (15.4-20.8)	

0.94 (0.93-0.94)

16.3 (14.2-18.3)

0.72 (0.69-0.75)

High

0.67 (0.64-0.70)

Supplementary Figure S7. Number of events, event rates, and hazard ratios (95% confidence intervals) on the association between income and non-persistence to **antiplatelets** as well as the mediating effect on the association between income and risk of MACE among **men**, adjusted for age and ethnicity.

				Non-persistence to a	ntiplatelets			
		U	nadjusted				Model I	
	No. of events	Event rate per 100,000 pr. yrs.		HR	No. of events	Event rate per 100,000 pr. yrs.		HR
Study pop	ulation I (in	icome as exposure)						
Low	2,183	18.3 (17.6-19.1)	•	1 (reference)	2,356	18.1 (17.3-19.0)	+	1 (reference)
Middle	2,222	14.8 (14.2-15.4)	HEH	0.81 (0.76-0.86)	2,282	14.8 (14.2-15.4)	HIIH	0.82 (0.77-0.87)
High	2,311	14.0 (13.4-14.5)	н	0.76 (0.71-0.80)	2,605	16.0 (15.3-16.8)	н	0.87 (0.81-0.93)
Study pop	ulation II (e	education as exposu	re)					
Low	2,253	15.8 (15.2-16.5)		1 (reference)	2,228	15.3 (14.7-16.0)		1 (reference)
Middle	3,056	14.6 (14.0-15.1)	ншн	0.92 (0.87-0.97)	3,109	14.9 (14.4-15.5)	H-4	0.98 (0.92-1.03)
High	1,407	17.1 (16.2-18.0)		1.07 (1.01-1.15)	1,413	17.2 (16.3-18.1)	н	1.12 (1.05-1.20)
				_				<u></u>
			0.7 1	1.3			0.7 1	1.3
		T	he mediating ef	ffect of non-persistenc	e to antiplate	lets among men		

The mediating effect of non-persistence to antiplatelets among men										
Level of income	Total effect (HR, 95% CI)	Direct effect (HR, 95% CI)	Indirect effect (HR, 95% CI)	Mediated proportion (%)						
Low	1 (reference)	1 (reference)	1 (reference)	1 (reference)						
Middle	0.78 (0.75-0.81)	0.81 (0.77-0.84)	0.97 (0.97-0.97)	11.8 (10.1-13.6)						
High	0.67 (0.64-0.70)	0.69 (0.66-0.72)	0.97 (0.97-0.98)	6.5 (5.7-7.4)						

Supplementary Table S1. ICD-10 codes, ATC-codes, and procedure codes used in present study

Main diagnosis	ICD-10 co	des
Acute coronary syndrome	I200, I21, I	T24
Outcome/diagnosis		
Cardiac death	I20-I25	
Acute cardiac readmission:		
Acute myocardial infarction	I21-I22	
Stroke	I60-I64	
Cardiac arrest	I46	
Chronic heart failure		0, I42.6, I42.8, I50
Ventricular tachycardia or fibrillation	II49.0	0, 142.0, 142.0, 150
Mediator	ATC code	
Antiplatelets		B01AC06, B01AC22, B01AC24
Statins	C10AA	BUTACUO, BUTAC22, BUTAC24
		and a
Procedures Department of the second of the	Procedure	
Percutaneous coronary intervention		KFNG01, KFNG02, KFNG05, KFNG10, KFNG12,
CL L C LIPETI		KFNG22, KFNG30, KFNG40, KFNG96, KZFX01
Charlson Comorbidity Index	Assigned	ICD-10 Code
ANT	weighting	101 100 102 1410
AMI	1	I21, I22, I23, I410
CHF	1	150, 1110, 1130, 1132
Peripheral vascular disease	1	170, 171, 172, 173, 174, 177
Cerebral vascular accident	1	G45, G46, I60, I61, I62, I63, I64, I65, I66, I67, I68, I69
Dementia	1	F00, F01, F02, F03, F051, G30
Pulmonary disease	1	J40, J41, J42, J43, J44, J45, J46, J47,
		J60, J61, J62, J63, J64, J65, J66, J,67, J684
		J701, J703. J841, J920, J961, J982, J983
Connective tissue disorder	1	M05, M06, M08, M09, M30, M31, M32, M33, M34, M35
		M36, D86
Peptic ulcer	1	K221, K25, K26, K27, K28,
Mild liver disease	1	B18, K700, K701, K702, K703, K709, K71, K13, K74,
		K760
Diabetes without complications	1	E100, E101, E109, E110, E111, E119,
Diabetes with chronic complications	2	E102, E103, E104, E105, E107, E108, E112, E113, E114,
		E115, E117, E118
Hemiplegia	2	G81, G82
Renal disease	2	I12, I13, N00, N01, N02, N03, N04, N05, N07, N11, N14,
		N17, N18, N19, Q61
Any tumour	2	C00, C01, C02, C03, C04, C05, C06, C07, C08, C09, C10
•		C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21
		C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32
		C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43
		C44, C45, C46, C47, C48, C49, C50, C51, C52, C53, C54
		C55, C56, C57, C58, C59, C60, C61, C62, C63, C64, C65
		C66, C67, C68, C69, C70, C71, C72, C73, C74, C75
Leukaemia	2	C91, C92, C93, C94, C95
Lymphoma	2	C81, C82, C83, C84, C85, C88, C90, C96
Moderate or severe liver disease	3	B150, B160, B162, B190, K704, K72, K766, I85,
Metastatic solid tumour	6	C76, C77, C78, C79, C80
Aids/HIV	6	B21, B22, B23, B24
Psychiatric comorbidity	ICD-10 co	
Depression, Anxiety, OCD		N06A excluding N06AX12 and N06AX21
Deplession, Anxiety, OCD	F32, F33	
	F40-F42	N05B and N05C excluding N05CH01

Supplementary Table S2. Baseline characteristics of study population II (education as exposure) stratified by sex.										
		Men		•	Women					
	Low	Middle	High	Low	Middle	High				
Characteristics	(n = 10,050)	(n = 14,329)	(n = 5.817)	(n = 7,079)	(n = 4,874)	(n = 2,292)				
Days of follow-up, median (25th-75th	1,020 (257-	1,130 (397-	1,167 (441-	977 (178-1,880)	1,150 (431-	1,222 (518-				
percentile)	1,957)	2,046)	2,042)		2,040)	2,034)				
Age (years), median + SD	65.3 (12.7)	62.9 (11.7)	63.6 (11.2)	71.4 (12.3)	65.7 (12.5)	64.6 (12.2)				
Age group (years), n (%)										
< 65 years	4,526 (45.0)	7,817 (54.6)	2,992 (51.4)	1,894 (26.8)	2,148 (44.1)	1,138 (49.7)				
65-74 years	2,854 (28.4)	4,101 (28.6)	1,825 (31.4)	1,933 (27.3)	1,436 (29.5)	622 (27.1)				
≥ 75 years	2,670 (26.6)	2,411 (16.8)	1,000 (17.2)	3,252 (45.9)	1,290 (26.5)	532 (23.2)				
Ethnicity, n (%)										
Immigrants/Descendants	777 (7.7)	990 (6.9)	610 (10.5)	312 (4.4)	264 (5.4)	163 (7.1)				
Income level, n (%)										
Low	4,190	3,539	660	4,163 (58.8)	1,551 (31.8)	318 (13.9)				
Middle	3,684	5,201	1,301	2,074 (29.3)	>1,873 (>38.3)	>745 (>32.5)				
High	2,155	5,551	3,844	833 (11.8)	1,442 (29.6)	1,225 (53.4)				
Missing	21	38	12	9 (0.1)	< 8 (<0.1)	<5(<0.2)				
Civil status, n (%)										
Single living	3.227 (32.1)	3,506 (24.5)	1,132 (19.5)	3,764 (53.2)	1,984 (40.7)	894 (39.0)				
Somatic comorbidity (CCI), n (%)										
None (0 points)	586 (5.8)	972 (6.8)	469 (8.1)	453 (6.4)	413 (8.5)	237 (10.3)				
Moderate (1-2 points)	7,667 (76.3)	11,262 (78.6)	4,663 (80.2)	4,939 (69.8)	3,625 (74.4)	1,716 (74.9)				
High (>2 points)	1,797 (17.9)	2,095 (14.6)	685 (11.8)	1,687 (23.8)	836 (17.2)	339 (14.8)				
Psychiatric comorbidity, n (%)										
Current (<90 days)	1,199 (11.9)	1,309 (9.1)	527 (9.1)	1,823 (25.8)	1,004 (20.6)	393 (17.1)				
Recent (90-365 days)	499 (5.0)	686 (4.8)	333 (5.7)	632 (8.9)	442 (9.1)	168 (7.3)				
Past (>365 days)	1,850 (18.4)	2,538 (17.7)	983 (16.9)	1,643 (23.2)	1,156 (23.7)	536 (23.4)				
None	6,502 (64.7)	9,796 (68.4)	3,974 (68.3)	2,981 (42.1)	2,272 (46.6)	1,195 (52.1)				
Prior treatment, n (%)										
Antiplatelets	3,465 (34.5)	4,782 (33.4)	1,848 (31.8)	3,193 (45.1)	1,811 (37.2)	789 (34.4)				
Statins	3,236 (32.2)	4,088 (28.5)	1,572 (27.0)	2,854 (40.3)	1,560 (32.0)	692 (30.2)				
Percutaneous coronary intervention, n (%)	4,515 (44.9)	6,745 (47.1)	2,768 (47.6)	2,236 (31.6)	1,735 (35.6)	884 (38.6)				

Supplementary Table S3: Events, event rates (95% CI), and hazard ratios (95% CI) for the association between **income** and risk of non-persistence to medication and clinical events using none or 30-days window of initiation of medication

No criteria

30 days

	No criteria 30 days					
	Low	Middle	High	Low	Middle	High
-	(n = 20,167)	(n = 20,167)	(n = 20,167)	(n = 12,652)	(n = 12,651)	(n = 12,651)
Major adverse cardiovascular event						
Unadjusted						
Events	10,952	8,412	5,858	6,010	4,371	3,332
Event rate per 100,000 person-years	55.4 (54.4-56.5)	37.6 (36.8-38.4)	23.4 (22.8-24.0)	42.0 (41.0-43.1)	27.6 (26.8-28.4)	20.8 (20.1-21.5)
Total effect, HR	1 (reference)	0.71 (0.70-0.73)	0.47 (0.46-0.48)	1 (reference)	0.68 (0.66-0.71)	0.52 (0.50-0.54)
Model 1						
Events	10,873	8,856	7,308	5,822	4,570	3,898
Event rate per 100,000 person-years	46.4 (45.1-47.6)	38.4 (37.4-39.4)	30.9 (29.8-32.0)	36.1 (34.9-27.3)	28.4 (27.4-29.3)	25.0 (23.8-26.2)
Total effect, HR	1 (reference)	0.82 (0.80-0.85)	0.66 (0.64-0.68)	1 (reference)	0.79 (0.76-0.82)	0.68 (0.65-0.71)
Model 2	0.027	0.740	0.700	7.0 00	4.550	
Events	9,935	8,768	9,700	5,298	4,578	5,215
Event rate per 100,000 person-years	41.1 (39.7-42.6)	37.8 (36.8-38.8)	40.4 (37.4-43.7)	32.4 (31.0-33.9)	28.4 (27.4-29.4)	31.8 (28.2-36.1)
Total effect, HR	1 (reference)	0.89 (0.87-0.92)	0.81 (0.78-0.85)	1 (reference)	0.86 (0.83-0.90)	0.81 (0.76-0.84)
Non-persistence to medication						
Unadjusted	< < 2.7		< 0.10	4.007	4 422	4.052
Unadjusted	6,627	6,338	6,213	4,985	4,423	4,053
Events	32.2 (31.5-33.0)	27.7 (27.0-28.4)	25.3 (24.6-25.9)	34.0 (33.1-35.0)	27.7 (26.8-28.5)	25.6 (24.8-26.4)
Event rate per 100,000 person-years	1 (reference)	0.86 (0.83-0.89)	0.78 (0.76-0.81)	1 (reference)	0.81 (0.78-0.85)	0.74 (0.71-0.77)
Total effect, HR	7.071	6.545	6.715	5 050	4.505	4.460
Model 1	7,371	6,545	6,745	5,272	4,587	4,460
Events	30.8 (30.0-31.7)	27.7 (27.1-28.4)	29.0 (28.1-29.9)	32.6 (31.6-33.7)	28.2 (27.4-29.0)	29.0 (27.9-30.2)
Event rate per 100,000 person-years Total effect, HR	1 (reference)	0.90 (0.86-0.93)	0.91 (0.88-0.95)	1 (reference)	0.87 (0.81-0.90)	0.87 (0.83-0.91)
Model 2	7,319	6,526	7,063	5,179	4,603	4,935
Events	30.5 (29.3-31.7)	27.7 (27.0-28.4)	29.3 (27.7-31.1)	32.3 (31.0-33.7)	28.4 (27.5-29.3)	30.1 (28.2-32.1)
Event rate per 100,000 person-years	1 (reference)	0.91 (0.87-0.95)	0.91 (0.86-0.96)	1 (reference)	0.88 (0.84-0.93)	0.88 (0.82-0.94)
All-cause death						
Unadjusted						
Events	7,452	4,458	2,097	3,296	1,569	801
Event rate per 100,000 person-years	27.5 (26.8-28.1)	15.3 (14.8-15.7)	6.8 (6.5-7.1)	16.7 (16.2-17.3)	7.6 (7.3-8.0)	4.0 (3.7-4.3)
Total effect, HR	1 (reference)	0.56 (0.54-0.57)	0.25 (0.24-0.26)	1 (reference)	0.46 (0.43-0.48)	0.24 (0.22-0.25)
Model 1						
Events	6,774	4,817	3,473	2,828	1,724	1,272
Event rate per 100,000 person-years	21.4 (20.8-22.0)	16.0 (15.5-16.5)	11.6 (11.0-12.3)	12.9 (12.5-13.5)	8.2 (7.8-8.6)	6.4 (5.9-7.0)
Total effect, HR	1 (reference)	0.75 (0.72-0.78)	0.52 (0.50-0.55)	1 (reference)	0.66 (0.62-0.70)	0.50 (0.45-0.54)
Model 2						
Events	6,006	4,800	5,520	2,440	1,776	2,116
Event rate per 100,000 person-years	18.8 (18.2-19.4)	15.9 (15.4-16.4)	18.0 (15.9-20.5)	11.2 (10.7-11.7)	8.5 (8.1-8.9)	10.1 (7.7-13.4)
Total effect, HR	1 (reference)	0.85 (0.81-0.88)	0.72 (0.67-0.78)	1 (reference)	0.78 (0.72-0.83)	0.67 (0.58-0.77)
Cardiac death						
Unadjusted	1.500	1 100	501	505	255	124
Events	1,766	1,109	501	705	375	164
Event rate per 100,000 person-years	6.5 (6.2-6.8)	3.8 (3.6-4.0)	1.6 (1.5-1.8)	3.6 (3.3-3.8)	1.8 (1.6-2.0)	0.8 (0.7-1.0)
Total effect, HR	1 (reference)	0.58 (0.54-0.62)	0.25 (0.23-0.28)	1 (reference)	0.51 (0.45-0.57)	0.22 (0.19-0.26)
Model 1						

Events	1,608	1.217	810	600	410	253
Event rate per 100,000 person-years	5.1 (4.8-5.3)	4.0 (3.8-4.3)	2.7 (2.4-3.0)	2.7 (2.5-3.0)	2.0 (1.8-2.2)	1.3 (1.1-1.5)
Total effect, HR	1 (reference)	0.79 (0.73-0.85)	0.51 (0.46-0.57)	1 (reference)	0.72 (0.64-0.82)	0.46 (0.37-0.55)
Model 2						
Events	1,410	1,240	1,266	521	422	376
Event rate per 100,000 person-years	4.4 (4.2-4.7)	4.1 (3.9-4.4)	4.1 (3.3-5.2)	2.4 (2.2-2.6)	2.0 (1.8-2.2)	1.8 (1.3-2.4)
Total effect, HR	1 (reference)	0.93 (0.85-1.01)	0.71 (0.60-0.84)	1 (reference)	0.87 (0.75-1.00)	0.58 (0.43-0.79)
Cardiac readmission						
Unadjusted						
Events	7,099	6,031	4,721	4,537	3,619	2,933
Event rate per 100,000 person-years	35.9 (35.1-36.8)	26.9 (26.3-27.6)	18.9 (18.4-19.4)	31.7 (30.8-32.7)	22.9 (22.1-23.6)	18.3 (17.7-19.0)
Total effect, HR	1 (reference)	0.81 (0.78-0.83)	0.61 (0.59-0.63)	1 (reference)	0.76 (0.73-0.79)	0.62 (0.59-0.64)
Model 1						
Events	7,336	6,239	5,477	4,532	3,738	3,322
Event rate per 100,000 person-years	31.3 (30.3-23.3)	27.0 (26.3-27.8)	23.1 (22.2-24.1)	28.1 (27.0-29.2)	23.2 (22.4-24.1)	21.3 (20.2-22.4)
Total effect, HR	1 (reference)	0.86 (0.84 (0.89)	0.74 (0.72-0.77)	1 (reference)	0.83 (0.80-0.86)	0.74 (0.71-0.78)
Model 2						
Events	6,804	6,157	6,800	4,180	3,724	4,272
Event rate per 100,000 person-years	28.2 (27.0-29.3)	26.5 (25.8-27.4)	28.4 (26.0-31.0)	25.6 (24.4-26.9)	23.1 (22.2-24.0)	26.1 (23.2-29.4)
Total effect, HR	1 (reference)	0.91 (0.88-0.94)	0.86 (0.82-0.92)	1 (reference)	0.89 (0.85-0.93)	0.87 (0.80-0.94)

Model 1: Weighted by/ adjusted for age group, sex, ethnicity.

Model 2: Weighted by/ adjusted for age group, sex, ethnicity, civil status, somatic and psychiatric comorbidity.

Supplementary Table S4. Events, event rates (95% CI), and hazard ratios (95% CI) for the association between **education** and risk of non-persistence to medication and clinical events using none or 30-days window of initiation of medication

incurcation and crimear events using none of	30 days window of initiatio	No criteria	30 days			
	Low $(n = 23,451)$	Middle (n = 24,201)	High $(n = 10,389)$	Low $(n = 13,962)$	Middle $(n = 16,085)$	High $(n = 6.891)$
Major adverse cardiovascular event						
Unadjusted						
Events	12,102	9,559	3,561	6,109	5,501	2,103
Event rate per 100,000 person-years	48.7 (47.8-49.6)	32.7 (32.0-33.3)	27.3 (26.4-28.2)	37.0 (36.1-37.9)	26.6 (25.9-27.4)	23.4 (22.5-24.5)
Total effect	1 (reference)	0.73 (0.72-0.75)	0.63 (0.61-0.65)	1 (reference)	0.76 (0.73-0.78)	0.67 (0.64-0.70)
Model 1						
Events	11,210	10,078	3,796	5,702	5,748	2,185
Event rate per 100,000 person-years	42.4 (41.4-43.4)	35.4 (34.6-36.3)	30.1 (29.0-31.2)	33.2 (32.2-34.2)	28.3 (27.4-29.1)	24.7 (23.6-25.9)
Total effect	1 (reference)	0.86 (0.84-0.88)	0.75 (0.72-0.77)	1 (reference)	0.87 (0.84-0.90)	0.77 (0.74-0.81)
Model 2						
Events	10,571	10,215	4,161	5,392	5,808	2,381
Event rate per 100,000 person-years	39.8 (38.8-40.8)	36.0 (35.2-36.9)	31.8 (30.3-33.4)	31.5 (30.4-32.5)	28.7 (27.8-29.5)	25.7 (24.2-27.3)
Total effect	1 (reference)	0.92 (0.90-0.94)	0.88 (0.85-0.92)	1 (reference)	0.92 (0.89-0.95)	0.88 (0.84-0.93)
Non-persistence to medication						
Unadjusted						
Events	7,599	7,942	3,637	5,143	5,704	2,614
Event rate per 100,000 person-years	29.2 (28.5-29.9)	26.9 (26.3-27.4)	29.2 (28.3-30.2)	30.0 (29.1-30.8)	27.5 (26.8-28.2)	30.4 (29.2-31.6)
Total effect	1 (reference)	0.93 (0.90-0.96)	1.00 (0.96-1.04)	1 (reference)	0.92 (0.89-0.96)	1.01 (0.96-1.06)
Model 1						
Events	7,584	8,008	3,659	4,999	5,831	2,654
Event rate per 100,000 person-years	27.5 (26.8-28.1)	27.8 (27.2-28.5)	30.3 (29.3-31.3)	28.1 (27.3-28.9)	28.6 (27.8-29.4)	31.4 (30.2-32.7)
Total effect, HR	1 (reference)	1.00 (0.98-1.04)	1.09 (1.05-1.14)	1 (reference)	1.01 (0.97-1.05)	1.11 (1.06-1.17)
Model 2	, , , , ,					
Events	7,486	8,036	3,821	4,871	5,855	2,823
Event rate per 100,000 person-years	27.1 (26.4-27.9)	28.0 (27.4-28.7)	30.4 (29.1-31.7)	27.5 (26.6-28.4)	28.8 (28.0-29.6)	31.9 (30.4-33.6)
Total effect, HR	1 (reference)	1.03 (0.99-1.06)	1.14 (1.09-1.20)	1 (reference)	1.04 (1.00-1.08)	1.18 (1.12-1.25)
All-cause death		,	· · · · · · · · · · · · · · · · · · ·	,	` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` `	,
Unadjusted						
Events	7,60	4,711	1,636	3,051	1,934	681
Event rate per 100,000 person-years	23.0 (22.5-23.5)	12.5 (12.1-12.9)	10.0 (9.6-10.5)	13.7 (13.2-14.2)	7.2 (6.9-7.6)	6.0 (5.6-6.5)
Total effect	1 (reference)	0.56 (0.54-0.58)	0.45 (0.43-0.47)	1 (reference)	0.53 (0.50-0.56)	0.44 (0.40-0.48)
Model 1	· · · · · · · · · · · · · · · · · · ·	,	, ,	,	, , ,	,
Events	6,526	5,318	1,881	2,560	2,184	766
Event rate per 100,000 person-years	18.6 (18.1-19.0)	14.4 (14.0-14.9)	11.8 (11.3-12.4)	11.2 (10.8-11.6)	8.3 (7.9-8.7)	6.8 (6.3-7.3)
Total effect	1 (reference)	0.78 (0.75-0.81)	0.64 (0.61-0.68)	1 (reference)	0.74 (0.70-0.78)	0.62 (0.57-0.68)
Model 2	(/	,)	,		,	(
Events	5,925	5,479	2,110	2,301	2,252	847
Event rate per 100,000 person-years	17.0 (16.5-17.4)	14.9 (14.5-15.4)	12.6 (11.8-13.4)	10.2 (9.8-10.6)	8.5 (8.2-8.9)	7.1 (6.4-7.8)
Total effect	1 (reference)	0.86 (0.83-0.89)	0.82 (0.77-0.88)	1 (reference)	0.81 (0.76-0.86)	0.74 (0.67-0.83)
Cardiac death	(/	(== =====)	(((1. 1.1.2)
Unadjusted						
Events	1,900	1,094	382	684	406	154
Event rate per 100,000 person-years	5.7 (5.4-6.0)	2.9 (2.7-3.1)	2.3 (2.1-2.6)	3.1 (2.9-3.3)	1.5 (1.4-1.7)	1.4 (1.2-1.6)
2. on two per 100,000 person-years	3.7 (3.4-0.0)	2.7 (2.1-3.1)	2.3 (2.1-2.0)	3.1 (2.7-3.3)	1.5 (1.7-1.7)	1.7 (1.2-1.0)

Total effect	1 (reference)	0.54 (0.50-0.58)	0.44 (0.39-0.49)	1 (reference)	0.50 (0.44-0.56)	0.45 (0.38-0.53)
Model 1						
Events	1,625	1,235	432	580	453	169
Event rate per 100,000 person-years	4.6 (4.4-4.9)	3.4 (3.2-3.6)	2.7 (2.5-3.0)	2.5 (2.3-2.7)	1.7 (1.6-1.9)	1.5 (1.3-1.8)
Total effect	1 (reference)	0.73 (0.68-0.79)	0.60 (0.54-0.67)	1 (reference)	0.67 (0.59-0.76)	0.60 (0.50-0.71)
Model 2						
Events	1,491	1,271	471	518	467	185
Event rate per 100,000 person-years	4.3 (4.1-4.5)	3.5 (3.2-3.7)	2.8 (2.5-3.2)	2.3 (2.1-2.5)	1.8 (1.6-2.0)	1.5 (1.3-1.9)
Total effect	1 (reference)	0.80 (0.74-0.87)	0.74 (0.65-0.85)	1 (reference)	0.75 (0.66-0.86)	0.73 (0.58-0.91)
Cardiac readmission						
Unadjusted						
Events	8,077	7,085	2,689	4,745	4,574	1,770
Event rate per 100,000 person-years	32.5 (31.8-33.2)	24.2 (23.7-24.8)	20.6 (19.9-21.4)	28.7 (27.9-29.5)	22.2 (21.5-22.8)	19.7 (18.8-20.7)
Total effect	1 (reference)	0.83 (0.80-0.85)	0.73 (0.70-0.76)	1 (reference)	0.82 (0.80-0.85)	0.74 (0.71-0.78)
Model 1						
Events	7,807	7,282	2,794	4,551	4,713	1,811
Event rate per 100,000 person-years	29.5 (28.7-30.3)	25.6 (24.9-26.3)	22.1 (21.2-23.1)	26.5 (25.6-27.4)	23.2 (22.4-24.0)	20.5 (19.5-21.6)
Total effect	1 (reference)	0.94 (0.92-0.97)	0.90 (0.86-0.94)	1 (reference)	0.94 (0.91-0.97)	0.90 (0.86-0.95)
Model 2						
Events	7,471	7,344	3,071	4,363	4,749	1,986
Event rate per 100,000 person-years	28.1 (27.3-29.0)	25.9 (25.2-26.6)	23.5 (22.2-24.8)	25.4 (24.5-26.4)	23.4 (22.7-24.2)	21.4 (20.1-22.9)
Total effect	1 (reference)	0.94 (0.92-0.97)	0.92 (0.88-0.97)	1 (reference)	0.94 (0.90-0.97)	0.91 (0.86-0.97)

Model 1: Weighted by/ adjusted for age group, sex, ethnicity.

Model 2: Weighted by/ adjusted for age group, sex, ethnicity, civil status, somatic and psychiatric comorbidity.